Biopharma commercialization has always required more than a promising discovery. It takes the right team, the right timing, and often, the right kind of capital to move an idea from the university lab toward patients. My guest is Ruben Flores-Saaib, PhD, Senior Director of Investments and Business Development at Ligand Pharmaceuticals, a publicly traded biopharma company with a broad portfolio of partnered programs and approved medications. Ruben brings a rare perspective to this conversation because he has worked inside university tech transfer offices, life science companies, new company formation, and now the investment side of the industry. We talk about Ligand’s evolution from a traditional drug development company into one of the largest biopharmaceutical royalty financiers in the industry, and what that shift means for companies, universities, inventors, and tech transfer offices. Ruben explains how Ligand evaluates opportunities, why the company focuses on programs that address high unmet medical needs, and how non-dilutive capital can sometimes help late-stage biopharma programs move closer to approval and commercialization. He also shares what his time in university tech transfer taught him about the challenges of bringing academic innovation into the market. For tech transfer professionals, this is a practical look at how investment, commercialization strategy, and university innovation can intersect. Ruben talks through what makes a program a potential fit for Ligand, what universities should think about before exploring a royalty-based transaction, and why these conversations are really about matching capital needs with the right asset at the right stage. It’s a useful discussion for anyone thinking about how promising discoveries move beyond the institution and into the hands of companies, investors, and ultimately, patients. In This Episode: [04:24] Ruben Flores-Saaib explains how curiosity and a desire to add value have guided his career across industry, university tech transfer, and investment. [06:26] Time inside university tech transfer helped shape his understanding of how academic innovation moves through complex, sometimes inefficient commercialization pathways. [09:46] Ligand’s shift from traditional drug development to a royalty aggregator model created a more diversified portfolio with multiple shots on goal. [11:00] Royalty finance works by providing non-dilutive capital to late-stage biopharma companies in exchange for future royalties once products reach the market. [13:58] Programs that address highly unmet medical needs are especially attractive because they may have stronger clinical, regulatory, and commercial potential. [15:59] Ligand’s portfolio includes more than 100 partnered commercial and development-stage programs, with approved medications across several therapeutic areas. [18:56] A patient-centered investment lens is both a philosophical commitment and a business strategy, since meaningful therapies may face fewer commercial and reimbursement headwinds. [19:53] Ligand’s Captisol platform supports drug formulation and delivery, helping partners address solubility and bioavailability challenges across multiple approved products. [22:11] Capital can be provided directly to universities or academic centers in exchange for future royalty income, depending on the institution’s needs and the asset involved. [25:36] Inventors may also be part of royalty financing conversations, but Ruben emphasizes that these discussions should happen through the proper tech transfer channels. [26:03] The best first conversation starts with a clear look at the university’s licensed technologies, their development stage, and whether they address highly unmet needs. [28:15] Non-dilutive royalty capital can help late-stage licensees reach the finish line while potentially increasing future royalty returns for the academic institution. [30:06] One misconception is that royalty aggregators simply want to take a university’s best asset, when Ligand is also taking on substantial pre-approval risk. [32:11] Waiting until approval may lead to a better deal, but that choice comes with the major risk that the product may never make it through approval at all. [33:02] Royalty financing is gaining visibility as companies look for capital options beyond traditional venture funding and equity markets. [35:20] Ligand invests across royalty finance, M&A, project finance, and platform technology acquisitions while keeping a broad view across therapeutic areas. [37:15] Oncology, inflammatory disease, cardiology, pulmonary, kidney, and other areas continue to present opportunities where innovative treatments may meet major patient needs. [38:29] Ligand plans to keep focusing on new therapies that fill unmet medical needs, especially pre-approval investments under $100 million. [39:02] Researchers, inventors, and tech transfer professionals are encouraged to reach out if they have questions or potential programs that may fit Ligand’s model. Resources: AUTM Fall 2025 Connect and Collaborate Ligand Ruben Flores-Saaib - Ligand Rubén Darío Flores Saaib - LinkedIn Ligand Pharmaceuticals Royalty Portfolio
